-

Inaugural ‘State of Weight Care’ Report Reveals Employers are Grappling with How to Navigate Obesity Coverage

  • Nearly all surveyed employers acknowledge weight management is important preventive care, yet many have hesitations about which programs and benefits actually improve outcomes cost-effectively
  • Despite concerns, 26% of employers are planning to offer weight loss medication benefits within the next year to meet growing employee demand for weight care benefits
  • Found members share their top three needs for a weight loss benefit: access to an obesity medicine specialist, access to medications, and a personalized treatment plan

AUSTIN, Texas--(BUSINESS WIRE)--Found, a medically-assisted weight loss program, today released its inaugural State of Weight Care Report from a survey representing 500 large employers with a minimum of 5,000 employees each and more than 350 active individual Found members. The 2023 report illuminates what employers and benefits decision-makers need to do to support employees on their healthcare journeys. The survey revealed that nearly all (96%) employers acknowledge weight management is important to preventive healthcare; however, they deviate about what types of programs or weight management benefits they should adopt to adequately manage concerns around clinical efficacy, rising costs, and access to a reliable medication supply.

The report found that nearly one-third of employers currently include weight loss medications in their benefits packages. Another 62% of employers have experienced a recent increase in spend for GLP-1 medications, a class of drugs used to treat type 2 diabetes and obesity. Increased spend comes as demand for GLP-1s like Ozempic® and Wegovy® has skyrocketed over the past year, making discussions around access to medically assisted weight care commonplace and destigmatizing medically-assisted weight loss in the process.

Not everyone responds successfully to GLP-1 medications. In fact, up to 37% of the population may not reach clinically-significant weight loss with GLP1 alone. Prescribed weight loss medication should always be based on a person’s unique biology and be done in consultation with a medical provider who understands the latest clinical research in obesity medicine.

“Results from this year’s State of Weight Care Report indicate a culture shift, with increasing acknowledgment that obesity is a chronic disease, as opposed to a moral failing or solely the result of lifestyle choices. At the same time, it’s critically important to not confuse medications like GLP-1s short cuts or silver bullets in weight care,” said Sarah Jones Simmer, CEO, Found. “Especially amid an international GLP-1 shortage, these medications should be one option within a wide toolkit of medications and other complementary treatments, where prescription decisions are made based on clinical efficacy and appropriateness, not media-driven demand.”

Many of the employers surveyed indicated plans to incorporate anti-obesity medication or some form of weight management programming into their benefits in the next 12 months (26%), though hesitations remain about the clinical efficacy (35%), cost (29%), and weight bias and discrimination (17%). These concerns are compounded by a lack of cohesive clinical guidelines for obesity care, access to professional care specialists trained in obesity medicine, and the misinformed craze around GLP-1s.

Surveyed Found members revealed that access to anti-obesity medication is the most valuable weight care benefit their employers offer, with 67% of respondents ranking it number one compared to eight other benefit options. Overall, it's also ranked the top must-have element of any weight management program when evaluating available programs in the market. Members also place a high value on having access to an obesity medicine specialist and receiving a personalized treatment plan. The rise of telemedicine and the influx of digital health offerings during the pandemic have increased access and affordability to weight care solutions, but within an increasingly saturated marketplace, organizations struggle to find the right weight care solution that will actually improve outcomes and decrease cost.

“Limited specialized knowledge in obesity medicine creates a range of suboptimal treatment protocols that result in poorer outcomes and higher costs,” said Dr. Rekha Kumar, Chief Medical Officer, Found. “Employers and benefit decision-makers looking to adopt solutions to help their workforce make clinically responsible decisions related to weight management should seek comprehensive programs combining lifestyle changes that build on science-backed behavioral change programming along with medication. There is no one-size-fits-all approach to weight care—it all depends on what the provider specializing in obesity deems the most clinically-appropriate for each person.”

Effectively balancing clinical efficacy and costs in weight management is achievable. Programs and solutions that take a more holistic approach, backed by professional care specialists trained in weight care, can yield positive health outcomes for employees and cost savings for employers.

The State of Weight Care Report was sourced from a OnePoll survey consisting of 500 large employers with more than 5,000 employees each, as well as a survey of more than 350 individual Found members. To learn more, download the full report here.

About Found

Found is an evidence-based weight care solution that combines the best of modern medicine with lasting behavior change, access to personalized coaching and a supportive community. Centered around clinical care, Found provides its members with a comprehensive weight loss program that delivers long term, sustainable results. Found designs personalized treatments around every factor that make people unique, including biology, medical history, existent lifestyle, goals and more. Found’s members are supported by a team that includes providers to prescribe effective medication, and the best of consumer technology to provide behavioral health interventions delivered through our app for guidance on nutrition, movement, sleep and emotional health. Found is among the largest medically-assisted weight loss clinics in the country, having served 200,000+ Americans to-date. For more information, visit www.joinfound.com.

OnePoll Survey Methodology:

This random double-opt-in survey of 500 American benefits decision makers at companies with more than 5,000 employees was commissioned by Found and conducted between August 2 and August 4, 2023. It was conducted by market research company OnePoll, whose team members are members of the Market Research Society and have corporate membership to the American Association for Public Opinion Research (AAPOR) and the European Society for Opinion and Marketing Research (ESOMAR).

Found member survey methodology:

The Found member survey was conducted among Found members who have been with the program for at least one month. Participants were asked to respond to questions in an online survey to share their weight care experience, their motivations for joining a weight loss program and what they found most valuable in their journey. 354 Found members responded (n=354).

Found


Release Versions

More News From Found

Found Health Launches GLP-1 Microdosing Program for Early Metabolic Dysfunction

MIAMI--(BUSINESS WIRE)--Found, the doctor-designed telehealth platform specializing in personalized weight care since 2019, today announced the launch of its GLP-1 Microdosing Program. The program addresses a critical gap in preventive care: patients with early metabolic dysfunction often wait years for treatment until their condition worsens to meet traditional prescribing thresholds. "For too long, healthcare has ignored the sophisticated signals our bodies send about metabolic health—and wor...

Found Expands GLP-1 Access With Industry-Leading Formulary and Affordability

MIAMI--(BUSINESS WIRE)--Found, the leading specialized weight care telehealth platform developed by obesity specialists, today announced it will offer Wegovy® at $499 per month and Zepbound™ vials ranging from $349 to $699. These offerings are made available by prescribing to the innovative direct-to-consumer options developed by Novo Nordisk and Eli Lilly respectively: NovoCare Pharmacy & LillyDirect Pharmacy Solutions. This expansion creates one of the most comprehensive medication formul...

Found Expands Enterprise Offering with Strategic Executive Hires to Transform Employer-Sponsored Weight Care Solutions

AUSTIN, Texas--(BUSINESS WIRE)--Today, Found, a leader in comprehensive weight management solutions, announced the addition of three healthcare executives to its leadership team. Rob Watson, Chief Revenue Officer, Deepa Ravikumar, Senior Vice President of Clinical Strategy, and Brynna Pietz, Senior Vice President of Operations, will accelerate Found’s expansion into the employer benefits space while continuing to drive growth in its direct-to-consumer business. Since launching in 2019, Found ha...
Back to Newsroom